Complications of Intrathecal Baclofen Pump: Prevention and Cure by Awaad, Yasser et al.
International Scholarly Research Network
ISRN Neurology
Volume 2012, Article ID 575168, 6 pages
doi:10.5402/2012/575168
Research Article
Complications of Intrathecal BaclofenPump:
Prevention and Cure
Yasser Awaad,1,2 Tamer Rizk,2 IramSiddiqui,2 Norbert Roosen,3 Kelly Mcintosh,3
andG.MichaelWaines4
1Pediatric Neurology and Movement Disorder Program, Oakwood Health System, Dearborn, MI, USA
2Department of Pediatric Neurology, National Neurosciences Institute, King Fahad Medical City, Riyadh 11393, Saudi Arabia
3Department of Neurosurgery, Henry Ford Health Systems, Detroit, MI, USA
4Operating Room Services, Oakwood Health System, Dearborn, MI, USA
Correspondence should be addressed to Tamer Rizk, drtamergaber@gmail.com
Received 26 December 2011; Accepted 16 January 2012
Academic Editor: Y. Ersahin
Copyright © 2012 Yasser Awaad et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Increasingly, spasticity is managed with surgically implanted Intrathecal Baclofen pumps. Intrathecal Baclofen pump revision
surgery unrelated to programmable pump end-of-life is not uncommon, requiring special attention during pre-, intra-, and
postoperative management. We aimed to identify and describe complications of Intrathecal Baclofen pump as well as to report
avoidance and management of complications. Methods and Materials. Through 2002–2006, at the department of neurosurgery,
Henry Ford and Oakwood Health Systems, Intrathecal Baclofen pumps were implanted in 44 patients: 24 children versus 20
adults; 30 “primary-implant-patients”; 14 “revision-only patients”. We evaluated reasons for revision surgeries and diagnostic
workup requirements. Results. Eight primary-implant-patients required 14 revisions and 7 of revision-only patients needed 13
procedures.Sevenpatientswithslowlyincreasingbaclofen-resistantspasticityhadeither(i)unsuspectedpump-catheterconnector
defects, (ii) an X-ray-documented pump-catheter connector defect, (iii) X-ray-demonstrated fractured catheter with intrathecal
fragment. Implant infections occurred in 4 cases. Scintigraphy revealed occult CSF leakage N = 1 and intrinsic pump failure
N = 1. Conclusion. Intrathecal Baclofen pumps, although very gratifying, have a high, technique-related complication incidence
during implant life. Meticulous technique, high clinical suspicion, appropriate workup, and timely surgical management can
reduce surgical complications of Intrathecal Baclofen pump implantation.
1.Introduction
Intrathecal baclofen (ITB) is becoming a popular modality
for management of severe spasticity [1–3]. “Spasticity” is
deﬁned as hypertonia in which one or both of the follow-
ing signs are present (1) resistance to externally imposed
movement that increases with increasing speed of stretch
and varies with the direction of joint movement, and/or
(2) resistance to externally imposed movement rises rapidly
above a threshold speed or joint angle [4]. It is a sensorimo-
tor phenomenon related to the integration of the nervous
system motor responses to sensory inputs. Although most
commonly considered as a velocity-dependent increase to
tonic stretch, it is related to hypersensitivity of the reﬂex arc
and changes that occur within the central nervous system
(CNS),mostnotably,thespinalcord.InjurytoCNSresultsin
loss of descending inhibition, allowing for the clinical man-
ifestation of abnormal impulses. Muscle activity becomes
overactive. This is mediated at several areas of the stretch-
reﬂex pathway. Although spasticity is part of the upper
motor neuron syndrome, it is frequently tied to the other
presentationsofthesaidsyndrome.Contracture,hypertonia,
weakness, and movement disorders can all coexist as a result
of the upper motor neuron syndrome [5]. Spasticity is a
common phenomenon in patients with a wide variety of
neurological disorders like cerebral palsy, multiple sclerosis,
cardiovascularaccidents, strokes, traumatic brain, and spinal
cord injury [6, 7]. These patients not only suﬀer from
severe contractures and deformities but also severe pain that
incapacitates them.2 ISRN Neurology
Appropriate management of spasticity is dependent
upon diﬀerent treatment modalities and requirements. Sev-
eral oral and parenteral medications have been used to
treat spasticity; their mechanisms of action are diﬀerent
and they inﬂuence various aspects of the neuromuscular
pathophysiology. Benzodiazepines, for example, diazepam
exert a medullary and supraspinal inhibitory eﬀect mediated
by GABAA receptors [8–13]. Their dosing may need to be
progressively increased. Benzodiazepines can lead to habit-
uation; withdrawal symptoms may occur when the medi-
cation is abruptly discontinued [8–13]. Side eﬀects such as
sedation,memory,andattentiondeﬁcitsarenotuncommon.
Dantrolene acts directly on the skeletal muscle, without
interferencewiththeneurologicalcircuitry;itinhibitsrelease
ofsequesteredcalciumfromthesarcoplasmicreticulum[10].
Dantrolene can be used also very eﬀectively in combination
with diazepam [10]. Adverse eﬀects of dantrolene include
general muscle weakness, sedation, and occasionally hepati-
tis. A third group of antispasticity drugs are α2 adrenergic
agonists,forexample,clonidineandtizanidine[11,12].They
hyperpolarize the motor neuron cell membrane, and they
have an antinociceptive eﬀect, which may indirectly reduce
muscular hypertonia as well. Side eﬀects include drowsiness,
dizziness,nausea,lightheadedness,vertigo,ataxia,headache,
tolerance, and physical dependence. Long-term use is dis-
couraged because of strong abuse potential. The most useful
oral medication in the treatment of spasticity is baclofen, a
GABAB receptor agonist that causes presynaptic inhibition
of mono- and polysynaptic reﬂex pathways; it also works at
the spinal cord level after crossing the blood-brain barrier.
An increasing oral dose easily causes side eﬀects including
sedation, dizziness, weakness, and dizziness [14, 15].
ITB administration has been introduced, therefore, to
maximize Baclofen’s eﬀects and minimize its side eﬀects. It
has been shown to be useful in the majority of patients to
treat severe or intractable spasticity and dystonia leading
to a decrease in muscle spasms, pain, and an increase in
functional motor activity and control [16–18].
We set out to identify and describe complications of ITB
pump and to report avoidance and management of com-
plications. Sharing our knowledge regarding patients with
ITB is important because as a result of the increasing use of
this device, familiarity with the workup of possible implant
malfunctionisimportant.Theremaybediagnosticandtech-
nicaldiﬃculties.Theconsequencesofthepumpmalfunction
can be detrimental to the patient. Complications of ITB vary
from
(1) dose related:
(a) overdose,
(b) withdrawal,
(2) mechanical implant dysfunction:
(a) tear at metal connector to the pump (within
protective silicon covering),
(b) inappropriate trimming of catheter,
(3) retrieval of old intrathecal catheter fragment through
limited hemilaminotomy with durostomy leads to
CSFleakwithtractformationdisturbwoundhealing,
dehiscence, and infection.
Complications can decrease therapeutic eﬀect, thus need to
be identiﬁed and treated promptly.
2.Methods andMaterials
A retrospective observational study was conducted aiming
to analyze ITB pumps’ complications. The patients were
followed by single operative and clinical team at the depart-
ment of neurosurgery at our hospital: Henry Ford and
Oakwood Health Systems. After the approval of the hospital
internal review board, all ITB pumps inserted at our facility
through the period of 2002–2006 were identiﬁed (excluding
previously performed surgery outside our own personal
experience with our patients). A standardised technique for
ITB pump implantation was followed “as described later.”
Patients who had ITB pump insertion and reasons for
insertion were identiﬁed and reviewed. We identiﬁed those
patients who had revision surgery, reasons for revision, and
diagnostic workup needed to identify complications as well
as type of complications, type of treatment instituted to alle-
viate complication, and how to identify these complications
in the future. Since 2002 ITB pump was implanted in 44
patients:
(i) 23 F/21M,
(ii) 24 children (16 F/8M) versus 20 adults (7 F/13M),
(iii) 30 “primary-implant-patients” (Table 1) 16 children
(10 F/6M) &14 adults (5 F/9M),
(iv) 14 “revision-only-patients” (Table 2) 8 children (6
F/2M) versus 6 adults (2 F/4M).
Clinical charts and operative and imaging reports were
reviewed to evaluate reasons for revision surgery and diag-
nostic workup requirements.
Weanalyzedreasonsforrevisionsurgeriesanddiagnostic
workup requirements in order to identify these complica-
tions early and manage them accordingly.
3. Results
Slowly increasing baclofen-resistant spasticity was encoun-
tered in seven patients; four of them had unsuspected pump-
catheter connector defects with either: subcutaneously dis-
located intrathecal catheter n = 1, (Figure 1), X-ray-
documented pump-catheter connector defect n = 1, an
eight-years-old boy with posttraumatic spastic quadriplegia
and right-sided myoclonic intention tremor. He underwent
18mL ITB implant on 2002 with good spasticity control
then on 2005 left thalamic DBS was done with good tremor
control. In 2006, he developed withdrawal symptoms and
interventional radiology with pump injection showed tear
at metal connector to the pump within protective silicon
covering,sorevisionwithtrimmingofcatheterandexchange
of the pump to 40mL pump markedly reduced his BaclofenISRN Neurology 3
Table 1: ITB-implant Surgery patients.
ITB—implant surgery patient population (N = 44)
Age group Children Adults
Gender M F M F
ITB-indications for implantation
Cerebral palsy 7 13 8 1
Closed head injury 1 1 1 0
Multiple sclerosis 0 0 1 2
Dystonia 0 1 0 1
Spondylotic cervical myelopathy 0 0 4 0
Intra cranial hemorrhage secondary to hypertension 0 0 0 1
Spasticity 0 0 1 1
Table 2: ITB—revision surgery patients.
ITB—revision surgery “primary-implant-patient” population (N = 30)
Age Group Children Adults
Gender MFMF
Patients requiring revision 4121
8 patients required 17 revision procedures:
(i) 5 revision procedure for 5 patients,
(ii) 12 revision procedures for 3 patients.
ITB—revision surgery “revision-only-patient” population (N = 14)
Age Group Children Adults
Gender MFMF
Patients with previous surgery at outside institutions 2543
patients required 16 additional revision procedures.
(i) 4 patients with previous revisions at outside institutions 1030
(a) 4 patients with seven previous revision procedures at
outside institutions had 6 additional revision procedures in our institution.
(ii) 10 patients without previous revisions outside 1513
(a) 10 patients required 10 revision procedures following the primary implant procedure.
needs(Figure 2).X-raydemonstratedfracturedcatheterwith
intrathecalfragmentn = 2;theﬁrstpatientwasa12-year-old
boy with spastic quadriplegic CP required laminectomy. His
pump was implanted in 2000 with good spasticity control.
He underwent multiple revisions in 2001, 2003, and 2004. In
2003, imaging showed adhesive arachnoiditis at the catheter
tip. In 2005, he developed mild withdrawal symptoms. Plain
X-ray showed fractured catheter with intrathecal fragment.
Following retrieval of old IT catheter fragment through lim-
itedhemilaminotomywithdurotomy,followedbyplacement
of a new IT catheter and replacement of old 10mL pump
with new 40mL programmable pump, he did not show
further CSF accumulation any more. The second patient was
managed without laminectomy. Injection studies revealed
intrathecal pericatheter arachnoiditis: 53-year-old male with
spasticquadriplegicCPwithsecondaryscoliosis.Hisoriginal
ITB was implanted in 2000 with good spasticity control. In
2006, he showed increasing spasticity and scoliosis requiring
Baclofen increase. Plain X-ray showed perforating tear at
the metal connector to pump with connector protrusion.
Revision was done with catheter trimming; exchange of ITB
pump to 40mL pump resulted in marked reduction of his
Baclofenneeds.Theremainingthreepatientshadconnector-
related dye leakage n = 3.
Implant infections occurred in 4 cases (3 with multiple
previous revisions). The ﬁrst one was a three-year-old
boy with cerebral palsy, postpump exchange secondary to
manufacturer-related mechanical pump failure; his pump
was removed, covered with appropriate antibiotics, and then
reinsertion of a new pump without further complications
followed. The second case was a ﬁve-year-old boy with cere-
bral palsy, postabdominal wound dehiscence, and catheter
exposure; antibiotics failed to save the implant, so his pump
was removed followed by reinsertion of a new pump without
further complications. The third case was an eight-year-old
girl with cerebral palsy, postabdominal wound dehiscence,
and catheter exposure; her pump was removed; course of
appropriate antibiotics was given followed by reinsertion
of a new pump without further complications. The fourth
case was a twenty-eight-year-old male with cerebral palsy4 ISRN Neurology
Figure 1: Tear at metal connector to pump within protective sili-
cone covering.
 
Figure 2: perforating tear at metal connector to pump with protru-
sion of connector.
with P. aeruginosa in catheter left in situ during previous
pump removal (>1yr) at outside institution treated with
appropriate antibiotic. His new implant was not infected
Occult CSF leakage occurred in a 37-year-old male
with ITB implanted in 2003 with good spasticity control.
In 2004, he developed abdominal CSF collection. Pump
injection showed leakage, catheter tear was discovered at
pump connector site, and revision surgery was done. He
remained to have recurrent CSF collections at abdominal site
with negative pump injection studies. Post-LP Scintigraphy
revealed lumbar CSF tract. However, no speciﬁc CSF tract
was found intraoperatively n = 1, (see Figure 3); removal
of the old intrathecal catheter with extensive catheter tract
obliteration and placement of a new IT catheter resulted in
no further CSF accumulation anymore.
4. Discussion
The diﬀerence in eﬀectiveness between oral and intrathecal
administration of baclofen is due to a signiﬁcantly higher
drug concentration that can be achieved in the CSF through
ITB.Inaddition,thereisa4to1gradientindrugdistribution
between the caudal and rostral parts of the spinal cord
following ITB, thus providing for a beneﬁcial eﬀect at the
spinal level without undesired side eﬀects in the brain
[19].
Although ITB is highly gratifying, it has predominant
technique-related complications during implant life. Metic-
ulous surgical technique, high clinical suspicion, appropriate
workup, and timely surgical management are emphasized
to reduce surgical ITB complications. Thorough workup is
crucial to rule out implant system dysfunction if clinical
evaluation is atypical.
Obtaining preoperative imaging, at least a plain X-ray,
h a sb e e np r o v e nt ob eas a f ea n de ﬀective method of evalua-
tion, although in our centre we have a low threshold to
perform pump injection studies with contrast.
In our series, ITB—Revision Surgery for both groups
“Primary-Implant-Patient” and “Revision-Only-Patient”
Population (N = 44). 33 additional revision procedures per-
formed on 22 of 44 patients ITB surgery carry signiﬁcant
morbidity that needs extended care and hospitalization
requirements (Tables 1 and 2).
We recommend a standardised implantation technique
that can be used as a guide for a safer ITB implants and may
help reduce the incidence of complications.
5.StandardisedITBPump Implant Technique
During an informed consent, we elaborated on pros and
cons of continuing conservative therapy versus implantation
of the ITB. We also acquainted patient of the goals and
beneﬁts, possible risks, and complications. Preoperatively,
patient’sgeneralmedicalconditionwasassessedbyexcluding
infection, integrity of the contemplated operative sites, and
prophylactic antibiotic within one hour of the incision
time. Although the procedure can be performed using local
anesthesia and sedation, general anaesthesia was preferred
because many of the patients were children.
Incision should be long enough (i.e. 1.5 to 2  )t oe x p o s e
the wound suﬃciently and to minimize potential interaction
of the implanted catheter with the skin borders, which are
the predominant source of surgical infection.
Then, the lumbar puncture is performed using the 14G
Tuohy needle supplied by the manufacturer in the implant
kit. Once the needle tip is in adequate position and CSF ﬂow
is achieved, the slightly curved Tuohy needle tip needs to be
rotated superiorly in order to guide the catheter superiorly.
Theﬁrstcriticalpointiswhenthecatheterreachedthetip
of the Tuohy needle. It is preferable to check ﬂuoroscopically
thecorrectpositioning ofthecatheteratthispoint:especially
important is to ensure that the catheter travels into cranial
direction and that it is not looping on itself. The presence
of the guide wire and an additional small metallic bead at
the catheter tip makes ﬂuoroscopic tracking of the catheter
usually relatively easy. Once the initial correct positioning is
veriﬁed, the catheter can be advanced more, which generally
goes without diﬃculty. The ﬁnal level of the catheter is
determined by the relative spasticity of the upper versus theISRN Neurology 5
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Figure 3: Removal of old catheter with extensive catheter tract obliteration. No speciﬁc CSF tract was found. (ABD: Abdominal, ANT:
anterior, IMMED: immediately after dye administration, LAT: lateral, POST: posterior, RT: right).
lower extremities and to what extent spasticity control is
targeted for the upper versus the lower extremities.
If the catheter cannot be advanced easily, it is better to
leave it at that level instead of forcing it more. If the surgeon
decides that the catheter needs to be withdrawn because he
noted a looping or the catheter is primarily going into caudal
direction, the catheter should never be withdrawn by itself,
butrathertheTuohyneedleshouldbewithdrawn:otherwise,
thereisasigniﬁcantrisktocauseacutinortransectionofthe
catheter.
Once the catheter is in its ﬁnal position, a purse string
stitch is placed very close around the needle penetration
site through the fascia. Then the Tuohy needle is withdrawn
and subsequently the guide wire. Following removal of the
guide wire, the purse string stitch can be tied in such a way
that the intrathecal catheter cannot be moved easily anymore
through the fascia penetration site. Patency of the catheter
should be obvious by the appearance and continuous drip-
ping of CSF from the catheter end. The catheter is now also
anchored to the lumbar fascia with a manufacturer supplied
anchor, which is attached to the catheter and the fascia with
nonresorbable sutures. Take care that this does not result in
acute catheter angles that may lead to catheter obliteration.
Thus place the catheter in a subcutaneous location around
the patient’s ﬂank. The catheter end is clamped gently with a
rubber shod mosquito to avoid excessive CSF loss.
The abdominal portion of the procedure is usually done
at the time of successful lumbar puncture in order to save
overall procedural time. The abdominal incision is made and
a pocket is created in the subcutaneous adipose layer. The
pumppocketisdesignedsuchthatthepumpaccessportswill
notbeexactlyunderneaththeincisionline.Itisusefultohave
the pump placed on the patient’s abdominal fascia because
this facilitates secure attachment of the pump and tends to
prevent pump hypermobility that can interfere with future
pump access for either reﬁll or diagnostic purposes. The
pump cavity should be large enough to accommodate the
pump.Oncetheabdominalandthelumbarsitesareprepared
adequately and the intrathecal catheter is in situ and
anchored, a custom-bent tunneler is passed subcutaneously6 ISRN Neurology
from the abdominal site to the lumbar site. This requires
the tunneler to be substantially bent in order to follow the
patient’sﬂankaround,carefullypassingthetunnelerthrough
the subcutaneous layer usually without need for counter
incisions with guided assistance, tunneling direction towards
thelumbarincision.Itisimportanttomakesurethatenough
catheter remains within the lumbar wound to make a small
strain relief loop at that site. On the abdominal side, the
intrathecal catheter is trimmed as needed to avoid too much
looping catheter length but leaving enough material in place
tobeabletohavealoop.Atthispoint,thepumpitselfisﬁlled
with the baclofen solution as per manufacturer procedural
guidelines. Patency of the catheter is double-checked when
the rubber shod mosquito is removed form the catheter end.
Thepump-catheterconnectorisattachedtothecatheter:this
requires gentle manipulation of the catheter to advance it
into the connector. The pump is then placed into the pump
cavity created earlier, securing the pump to the fascia using
the suture loops of the pump. The excess catheter is gently
placed underneath the pump prior to securing the device in
situ.Wefeel,usingtheabove-mentionedprotocolcanreduce
the complications, which have been described above.
6. Conclusion
The knowledge of the peculiarities of ITB treatment is
important, as there is an increased risk for the patients if
these implants are not functioning well. The physician who
may be called upon to evaluate the ITB pump patient needs
to have good understanding of the diagnostic challenges
when faced with a possible device malfunction. This also
assumes with the familiarity with diagnostic and therapeutic
preimplant workup with surgical implant technique and
with the postimplant maintenance management.
ITB improves both spasticity and spasms. As a result of
reduced spasticity and spasms, patients will be able to sleep
better, become more independent with mobility, and their
ability to do self-care helps improve urinary function. A
decrease in muscle pain and fatigue that accompany spasm
may also be seen. Thus eﬀective Baclofen therapy can be
delivered using ITB pump, where eﬀects of baclofen are
maximised, while its side eﬀects are minimised.
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